FDA-cleared profile

Neuro Insight V1.0

Olea Medical S.A.S.

Neuro Insight V1.0 is an image processing solution. It is intended to assist appropriately trained medical professionals in their analysis workflow on neurological MRI images. Neuro Insight V1.0 is composed of two subsets, including an image processing application package (NeuroPro) and an optional user interface (Neuro Synchronizer). NeuroPro is an image processing application package that computes maps, extracts and communicates metrics which are to be used in the analysis of multiphase or monophase neurological MR images. NeuroPro can be integrated and deployed through technical integration environment, responsible for transferring, storing, converting formats and displaying of DICOM imaging data. Neuro Synchronizer is an optional dedicated interface allowing the viewing, manipulation, and comparison of neurological medical imaging and/or multiple time-points, including post-processing results provided by NeuroPro or any other results from compatible processing applications. Neuro Synchronizer is a medical image management application intended to enable the user to edit and modify parameters that are optional inputs of aforementioned applications. These modified parameters are provided through the technical integration environment as inputs to the application to reprocess outputs. If necessary, Neuro Synchronizer provides the user with the option to validate the information. Neuro Synchronizer can be integrated in compatible technical integration environments. The device does not alter the original medical image. Neuro Insight V1.0 is not intended to be used as a standalone diagnostic device and should not be used as the sole basis for patient management decisions. The results of Neuro Insight V1.0 are intended to be used in conjunction with other patient information and based on professional judgment to assist with reading and interpretation of medical images. Users are responsible for viewing full images per the standard of care.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
Neuro Insight V1.0 is an image processing solution. It is intended to assist appropriately trained medical professionals in their analysis workflow on neurological MRI images. Neuro Insight V1.0 is composed of two subsets, including an image processing application package (NeuroPro) and an optional user interface (Neuro Synchronizer). NeuroPro is an image processing application package that computes maps, extracts and communicates metrics which are to be used in the analysis of multiphase or monophase neurological MR images. NeuroPro can be integrated and deployed through technical integration environment, responsible for transferring, storing, converting formats and displaying of DICOM imaging data. Neuro Synchronizer is an optional dedicated interface allowing the viewing, manipulation, and comparison of neurological medical imaging and/or multiple time-points, including post-processing results provided by NeuroPro or any other results from compatible processing applications. Neuro Synchronizer is a medical image management application intended to enable the user to edit and modify parameters that are optional inputs of aforementioned applications. These modified parameters are provided through the technical integration environment as inputs to the application to reprocess outputs. If necessary, Neuro Synchronizer provides the user with the option to validate the information. Neuro Synchronizer can be integrated in compatible technical integration environments. The device does not alter the original medical image. Neuro Insight V1.0 is not intended to be used as a standalone diagnostic device and should not be used as the sole basis for patient management decisions. The results of Neuro Insight V1.0 are intended to be used in conjunction with other patient information and based on professional judgment to assist with reading and interpretation of medical images. Users are responsible for viewing full images per the standard of care.
Public source Exact FDA submission Checked 2026-09-01

Exact-submission indication text from the ACR AI Central model card. FDA labeling remains controlling.

Intended users
Appropriately trained medical professionals
Public source Exact FDA submission Checked 2026-09-01

Intended-user text reported in the exact-submission ACR model card.

Care setting and population
Research pending
Needs research Exact FDA submission Checked 2026-08-31

Confirm the intended care setting, patient population, and service line.

Workflow role
Detection, localization, or diagnostic support
Public source Exact FDA submission Checked 2026-09-01

Conservative normalization of explicit wording in an exact-submission source.

Required input
MR images or data. Inclusion criteria: Multiphase or monophase neurological MR images including FLAIR, T1, T2, T1g, diffusion (DWI), and DSC perfusion series in DICOM format
Public source Exact FDA submission Checked 2026-09-01

Conservative normalization of explicit wording in an exact-submission source.

Output and human action
The device computes and outputs parametric maps and metrics including ADC, CBF, CBV, CBV_Corr, K2, MTT, TTP, Tmax/Delay, and tMIP from DWI and DSC perfusion MRI series. It also provides intra- and inter-exam co-registration results (FLAIR-DWI, FLAIR-DSC, FLAIR-T1, FLAIR-T1g, FLAIR-T2, FLAIR-follow-up FLAIR). Results are intended to assist with reading and interpretation of neurological MRI images.
Public source Exact FDA submission Checked 2026-09-01

Clinical output reported in the exact-submission ACR model card.

Limitations
Research pending
Needs research Exact FDA submission Checked 2026-08-31

Confirm contraindications, unsupported populations, scanners, protocols, and known failure modes.

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K243681
FDA source Exact FDA submission Checked 2026-08-31
Modality
MRI
Public source Exact FDA submission Checked 2026-09-01

Imaging modality reported in the exact-submission ACR AI Central model card.

Anatomy
Head
Public source Exact FDA submission Checked 2026-09-01

Anatomy normalized from explicit exact-submission ACR model-card wording.

Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2025-07-23
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
The exact-submission ACR model card explicitly references DICOM in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Public source Exact FDA submission Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Deployment and data flow
On-premise
Public source Exact FDA submission Checked 2026-08-13

Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.

Security and privacy
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

FDA authorization does not establish the current commercial security posture. Request data-flow diagrams, hosting and retention details, access controls, audit logging, attestations, and incident-response documentation.

Training and support
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

Training, onboarding, competency, and support commitments are commercial implementation details that require current vendor documentation.

Monitoring and change control
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

Local acceptance testing, production monitoring, drift review, update control, and incident escalation require a current vendor and site-specific governance plan.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
Study type: Stand-Alone Performance. Cases: 30
Public source Exact FDA submission Checked 2026-09-01

Structured study metadata from the exact-submission ACR model card; this is not an independent evidence synthesis.

Reported sensitivity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
Needs research Exact FDA submission Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

Neuro Insight V1.0 regulatory performance study summary

Stand-Alone Performance · Population described in the exact-submission ACR model card

exact submission · Tested version: Exact product version not reported; regulatory study summarized for FDA submission K243681 · n=30 · Independence not established

K243681

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Vendor documentation pending
Vendor confirmation Exact FDA submission Checked 2026-08-13

FDA submission materials do not establish current commercial pricing. Request the pricing unit, term, minimum commitment, implementation fees, and included support from the vendor.

Reimbursement and coding
Research pending
Needs research Exact FDA submission Checked 2026-08-31

Determine whether any product-specific CPT/HCPCS pathway exists and separate it from billing for the underlying imaging service.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-04Last searched
16Fields reviewed
6Source classes checked
0Unreviewed PubMed leads
0Unreviewed trial leads
0Unreviewed FDA recall leads

Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, acr ai central product, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-02.

Alternatives

Related tools to compare

FDA-cleared K241121

MICSI-RMT

Microstructure Imaging, Inc.

MICSI-RMT is image-processing software for MRI image enhancement and noise reduction in head MRI images. The FDA material describes analysis of functional and diffusion MRI images...

Modality
MRI
Anatomy
Head
Decision
2024-07-17
FDA-cleared K232760

Swoop® Portable MR Imaging System®

Hyperfine, Inc.

The Swoop Portable MR Imaging System is a portable, ultra-low-field, bedside magnetic-resonance device for producing images that display the internal structure of the head where a...

Modality
MRI
Anatomy
Head
Decision
2023-10-06
FDA-cleared K230264

Ezra Flash

Ezra AI, Inc.

Ezra Flash is MR image-processing software used to reduce image noise in non-contrast MRI examinations acquired on 3-Tesla Siemens and GE scanners for sagittal T1, axial T2, and...

Modality
MRI
Anatomy
Head
Decision
2023-04-13
FDA-cleared K230208

Swoop® Portable MR Imaging System™

Hyperfine, Inc.

The Swoop Portable MR Imaging System is a bedside magnetic-resonance device for producing images that display the internal structure of the head where a full diagnostic...

Modality
MRI
Anatomy
Head
Decision
2023-02-22